Amgen (BUE:AMGN) Interest Expense

: ARS-849,743 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Amgen's interest expense for the three months ended in Dec. 2023 was ARS -296,381 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was ARS-849,743 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Amgen's Operating Income for the three months ended in Dec. 2023 was ARS 458,831 Mil. Amgen's Interest Expense for the three months ended in Dec. 2023 was ARS -296,381 Mil. Amgen's Interest Coverage for the quarter that ended in Dec. 2023 was 1.55. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amgen Interest Expense Historical Data

The historical data trend for Amgen's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amgen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-77,048.17

-102,701.56

-120,885.03

-235,715.89

-1,037,875.00

Amgen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense																-69,574.75	-107,269.65	-180,480.00	-265,612.06	-296,381.00

Amgen Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-849,743 Mil.

Amgen (BUE:AMGN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Amgen's Interest Expense for the three months ended in Dec. 2023 was ARS-296,381 Mil. Its Operating Income for the three months ended in Dec. 2023 was ARS458,831 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was ARS22,804,370 Mil.

Amgen's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	458831	/	-296381
	=	1.55

The higher the ratio, the stronger the company's financial strength is.

Amgen (BUE:AMGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amgen Inc (BUE:AMGN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AMGN:USA AMG N:Mexico AMGd:UK 0R0T:UK AMG:Germany AMGN34:Brazil AMGN:Austria

Address

One Amgen Center Drive, Thousand Oaks, CA, USA, 91320-1799

Website

https://www.amgen.com

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.